C4 Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€29.38M - Cost of goods sold
€3.28M - Gross profit
€26.10M - SG&A expenses
€33.01M - R&D expenses
€100.92M - EBITDA
-€96.52M - D&A
€4.20M - EBIT
-€106.06M - Interest expenses
€0.00 - EBT
-€95.62M - Tax expenses
€112.40K - Net income
-€95.74M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€5.29M - Changes in working capital
-€7.18M - Operating cash flow
-€75.00M - Capex
€144.14K - Other investing cash flow
€0.00 - Net investing cash flow
€70.25M - Total cash dividends paid
€0.00 - Issuance of common stock
€8.82M - Debt repayment
€0.00 - Other financing cash flow
€349.21K - Net financing cash flow
€9.07M - Foreign exchange effects
€0.00 - Net change in cash
€7.28M - Cash at end of period
€70.01M - Free cash flow
-€74.85M
Balance sheet
- Cash and cash equivalents
€67.06M - Cash and short-term investments
€184.09M - Total receivables
€1.85M - Inventory
€0.00 - Other current assets
€6.88M - Total current assets
€192.82M - Property, plant & equipment
€51.27M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€10.18M - Other non-current assets
€152.72K - Total non-current assets
€61.60M - Total assets
€254.42M - Accounts payable
€1.90M - Short-term debt
€10.41M - Other current liabilities
€6.42M - Total current liabilities
€38.14M - Long-term debt
€97.57M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€66.93M - Total liabilities
€105.07M - Common stock
€6.01K - Retained earnings
-€588.62M - Other equity
-€25.74K - Total equity
€149.35M - Total liabilities and shareholders' equity
€254.42M
Company information
- Market capitalization
€84.79M - Employees
110 - Enterprise Value
€121.00M
Company ratios
- Gross margin
-
88.8% Much better than peer group: -1,089.5% - EBITDA margin
-
-328.5% Much better than peer group: -4,921.3% - EBIT margin
-
-361.0% Much better than peer group: -5,076.0% - EBT margin
-
-325.5% Much better than peer group: -4,844.5% - Net margin
-
-325.9% Much better than peer group: -4,777.7% - ROE
-
-64.1% Much better than peer group: -566.5% - ROA
-
-37.6% Much better than peer group: -110.1% - Asset turnover
-
11.5% Worse than peer group: 25.8% - FCF margin
-
-255.8% Much better than peer group: -4,211.8% - FCF yield
-88.6% - Efficiency ratio
428.5% - Net sales per employee
-
€267.07K - Net income per employee
-
-€870.33K